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SlLlmmary 
Due to local variation in the antigenicity of the agent of Lyme disease (Borrelia burgdorferi), a 
vaccine derived from any one isolate of this spirochete may fail to protect against the heterogeneous 
population of organisms that may be present in an enzootic focus. Accordingly, we determined 
whether antigenically variable spirochetes  delivered by naturally infected ticks, collected  from 
a site where transmission is intense, may fail to infect mice actively immunized with recombinant 
glutathione transferase outer surface fusion proteins A or B (OspA and OspB). Virtually all mice 
vaccinated by either immunogen appeared not to become infected, as determined by culture or 
histopathology of their tissues. We conclude that Osp vaccination of mice effectively prevents 
infection by the agent of Lyme disease in a simulated natural cycle of transmission. 
T 
he  outer  surface  proteins  (OspA  and  OspB)  of the 
spirochetal agent of Lyme disease (Borrelia burgdorfen)  hold 
promise as immunogens for delivery in vaccines designed to 
reduce risk of human Lyme disease (1, 2). Mice actively im- 
munized with OspA cloned from the N40 strain of spirochetes 
(herein designated OspA-N40) are protected against a syringe 
challenge by the same spirochetal isolate. Recombinant OspB 
antigen cloned from strain B31 (OspB-B31) (3) similarly pro- 
tects mice against homologous syringe challenge.  Vaccina- 
tion by recombinant OspA-N40 also protects against homol- 
ogous challenge via the bites of nymphal deer ticks (Ixodes 
dammini) (4). 
Isolates of the Lyme disease spirochete frequently differ an- 
tigenically, even when taken from the same site (5-7). Vari- 
ability mainly affects the Osps and is particularly evident in 
European isolates (8, 9). Indeed, vaccination with OspA-N40 
did not protect mice against syringe challenge by heterolo- 
gous spirochetes  (strain  25015) in which the OspA differs 
by 40 amino acids (10). Similarly, vaccination with OspB- 
B31 did not protect against challenge with N40 spirochetes 
(3). Because protective immunity may be strain or site specific 
(11), these laboratory studies suggest that a monotypic recom- 
binant antigen may have limited value as a vaccine. 
Although the OspA-N40 vaccine effectively protects mice 
1 S. R. Telford and E. Fikrig made equivalent contributions to this work. 
against experimental homologous tick-borne spirochetal in- 
fection (4), naturally occurring spirochetal variants may evade 
this induced immunity. To examine this suggestion, we per- 
mitted nymphal deer ticks taken from vegetation in an in- 
tensely enzootic site to engorge upon mice treated with recom- 
binant OspA or OspB immunogen and determined whether 
vaccination  effectively  neutralizes  these  naturally  derived 
spirochetes. 
Materials and Methods 
Nymphal and adult deer ticks were collected  by dragging from 
vegetation  on the property of the University  of Massachusetts  Nan- 
tucket Field Station (Nantucket, MA) during  June 1992. This site 
has previously been described (12). About 40% of host-seeking 
nymphs taken there contain Lyme disease spirochetes.  Between 50 
and 80 cases of Lyme disease are diagnosed each summer at the 
local hospital (S. R. Telford  III, unpublished observations). Thus, 
this site is taken to represent the general venue of Lyme disease 
transmission in the northeastern United States. 
Recombinant Osp's were expressed and purified as a fusion pro- 
tein with glutathione transferase as previously  described  (1). Briefly, 
the gene for OspA-N40 was ligated into plasmid pGEX-2T, and 
used to transform Escherichia  coil Fusion  protein production was 
induced with isopropyl 3  D-thiogalactopyranoside  (IFIG),  and 
purified using a glutathione sepharose 4B column. Female, 3-4- 
wk-old C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME) 
were actively  immunized  with 10 #g of  recombinant  OspA or OspB 
fusion proteins in CFA, and boosted with the same amount of pro- 
755  J.  Exp.  Med.  ￿9  The Rockefeller  University Press  ￿9 0022-1007/93/08/0755/04 $2.00 
Volume 178  August 1993  755-758 tein in IFA on days  7 and 14. For comparison, the glutathione trans- 
ferase carrier was similarly injected into other mice. 
To challenge immunized mice, five field-derived  nymphal ticks 
were permitted to attach to each host 4 wk after the series of im- 
munizations was completed. All ticks were permitted to feed to 
repletion and to detach naturally over water. Engorged ticks were 
retained for 10 d at room temperature, at which time they were 
examined for the presence of spirochetes by means of darkfield mi- 
croscopy and indirect immunofluorescence using polyclonal or 
monoclonal antibodies to R burgdorferi, as described (4). In addi- 
tion, lysates  from randomly selected ticks were placed in Barbour- 
Stoenner-Kdly (BSK II) culture medium and incubated at 32~ 
for 4 wk. Cultures were examined  by darkfield microscopy  for the 
presence of spirochetes. 
To determine whether immunized mice became infected after 
challenge by naturally infected ticks, selected tissues were excised 
and cultured or examined for pathognomonic lesions. Mice were 
killed 1 mo after the ticks had engorged. Blood, spleen, bladder, 
and skin were collected  aseptically  from each mouse, homogenized 
(spleen and bladders), and cultured in BSK II medium. Cultures 
were incubated for 2 wk and examined by darkfield microscopy. 
Joints (knee and tibiotarsal) and hearts were fixed in 10% neutral 
buffered  formalin,  embedded  in paraffin,  sectioned,  and stained  with 
hematoxylin and eosin. Inflammation within the joints or carditis 
(13, 14) were considered as evidence  of disease. All such slides were 
examined without knowledge of immunization status. 
To determine whether spirochetes  infecting ticks collected  from 
the Nantucket Field  Station site may  be antigenicaUy  variable, aliquots 
of tick gut homogenates were stained by indirect immunofluores- 
cence using a battery of mAbs. Briefly,  intact guts were dissected 
from six adult L dammini collected  from the identical  transects  from 
which  the  challenge nymphs were collected, and individually 
homogenized in 500 #1 of PBS (pH 7.2) with 0.5% BSA. After 
a 10-s low-speed centrifugation to pellet gross tissue debris and 
cuticle, aliquots of 5 #1 were spotted onto wells of 12-weU IFA slides 
(Cel-Line, Newfield, NJ), dried at room temperature, and fixed 
in cold acetone  for 10 min. mAbs against OspA (H5332 and H3TS, 
courtesy of A. G. Barbour; and IXDII87, 8C4B5C, and VIIIC378 
[3]), flagellin  (H9721 and H604, A. G. Barbour), and OspB (H6831, 
A. G. Barbour) were applied as undiluted hybridoma supernatants. 
High-titered rabbit immune serum and normal rabbit serum were 
applied as comparisons. After incubation for i h, and brief washing 
in PBS, appropriate secondary antibodies (antirabbit IgG or poly- 
valent antimouse Ig) labeled with FITC were applied to the slides, 
and allowed to react for 30 min. The slides were washed in PBS, 
mounted in glycerol, coverslipped, and examined  by epifluorescent 
microscopy at  x 312. All spirochetes with 3 +  fluorescence  were 
counted within each 5-#1 aliquot. Each antibody was applied to 
three replicate aliquots of homogenate from each tick. Counts de- 
rived for each mAb were pooled for all ticks with respect to an- 
tigen (e.g., OspA or flagellin), and examined by analysis of vari- 
ance (ANOVA). 
Results  and Discussion 
First, we determined whether spirochetes delivered by nat- 
urally infected nymphal ticks infect mice that had been im- 
munized either with recombinant OspA or OspB immunogen. 
No spirochetes  could be cultured from the tissues of any of 
these vaccinated mice (Table 1), and suggestive histopatho- 
logical lesions  could be detected only in one individual of 
each vaccinated group of mice. In contrast, spirochetes mul- 
Table  1.  Efficacy of Protection by Vaccination with Recombinant 
Spirochetal Osp's 
Immunogen 
Challenged mice 
No.  Percent  Percent  Percent 
mice  culture  with  with 
examined  positive  arthritis  carditis 
OspA  24  0  4  0 
OspB  17  0  0  6 
GT  32  34  41  44 
Tissues were taken from tick-challenged  mice 1 mo after infection,  and 
assayed for evidence of infection  by culture or histopathology. 
tiplied in cultures inoculated with ear skin taken from about 
a  third  of  carrier-immunized  mice  (X  2,  p  <0.01),  and 
pathognomonic lesions were noted in almost half (carditis, 
p <((0.01; arthritis, p <(0.001). We concluded that either Osp 
immunogen protects mice against infection by field-derived, 
tick-transmitted spirochetes. 
Because protection appears to derive in part from immune- 
mediated destruction of spirochetes  within the gut of the 
vector (4), we determined whether engorged ticks retained 
spirochetal  infection (Table 2).  Spirochetes  were evident in 
fewer ticks that had fed on Osp-vaccinated  mice than in those 
that had fed on sham-vaccinated mice (p <0.001 and <(0.05, 
respectively).  Spirochetes  native to Nantucket Island do not 
survive when exposed  to immune factors induced by vacci- 
nation with either Osp antigen. 
We demonstrated that spirochete populations within the 
guts of ticks collected from the Nantucket site are antigeni- 
cally variable by examining their reactivity with various mAbs 
against OspA, OspB, and flagellin.  In comparison with the 
number of spirochetes  per aliquot of gut homogenate that 
reacted  with  a  polyclonal  rabbit  immune  serum,  fewer 
Table  2.  Elimination of Spirochetal Infection from  the Guts 
of Ticks Engorging on  Vaccinated Mice 
Challenge ticks 
No.  Percent 
Immunogen  examined  infected 
OspA  34  3 
OspB  19  11 
GT  38  37 
Ticks used to challenge  vaccinated  mice were examined  for evidence  of 
infection 10 d after feeding to repletion. 
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two groups of anti-OspA mAbs, or with those against OspB 
or flagellin (ANOVA, f  =  6.55; df =  4; p <0.05). Spirochetes 
with reactive OspB, in particular,  appeared to be rare com- 
pared with those with reactive OspA (OspB mean,  17.9 per 
5 #1 vs. OspA mean,  124.3 per 5 #1; p <0.001 by Student's 
t test). The possibility that tick gut-derived spirochetes were 
differentially reactive because of differences in titer or staining 
efficiency of the various mAbs that were used was excluded 
by a similar experiment using 5-#1 aliquots of BSK-cultured 
B31 spirochetes, identical concentrations of reagents,  and iden- 
tical incubation times. Culture-derived spirochete counts did 
not differ between the various treatments  with  the mAbs 
(ANOVA, f  --  1.53;  df  --  4; p  >0.10).  We conclude that 
spirochetes within  ticks collected from the Nantucket  site 
are  antigenically  heterogeneous. 
These observations suggest that although antigenic vari- 
ability in products of the Osp operon (15,  16) may be fre- 
quent in nature,  vaccine-induced immunity is not affected. 
Because the mouse reservoir hosts are repeatedly exposed to 
infection, with each mouse receiving as many as six to eight 
infectious bites each month (S. K. Telford III, unpublished 
observations), it may be that ticks acquire diverse spirochetal 
clones. The epidemiological significance of antigenic variability 
within the guts of ticks, however, remains speculative. Only 
a few spirochetes appear to be transmitted by infecting ticks 
(17, 18), perhaps between 100 and 1,000. The likelihood,  there- 
fore, that  an vaccine escape variant will be transmitted by 
an infecting tick seems remote. Osp mutant spirochetes present 
within a zoonotic site thus may only rarely cause vaccine failure. 
We were surprised to find that protection is conferred by 
the OspB immunogen as well as by that produced by OspA. 
Because OspB appears to be more variable than OspA (6), 
the efficacy of an OspB-based vaccine might be expected to 
be less than one based on OspA. On the other hand, it may 
be that naturally occurring OspB variants are poorly infec- 
tions or less pathogenic than spirochetes containing the pro- 
totypic OspB-B31. Few spirochetes within the guts of the 
Nantucket ticks reacted with mAb H6831. Perhaps many ticks 
in nature contain poorly infectious, OspB variant spirochetes 
that  are morphologically indistinguishable  from those that 
are infectious. The effects of anti-OspB immunity may thus 
be more effective by destroying the few "infectious" spirochetes 
within  the guts of ticks. 
Vaccines containing the OspA or OspB epitopes may as- 
sist efforts designed to reduce risk of human Lyme disease. 
The agent of Lyme disease has been enzootic on Nantucket 
as long as it has elsewhere in the northeastern United States 
(19). Indeed, the Lyme disease epidemic seems to have begun 
there even before it emerged in coastal Connecticut in 1974. 
Nantucket may thus be representative of other coastal north- 
eastern U.S.  zoonotic sites,  which account for as much  as 
90% of the Lyme disease cases reported in the U.S. each year 
(20). Even if the efficacy of Osp vaccination does not extend 
worldwide,  local  vaccine  protection  would  constitute  a 
noteworthy public health  achievement. 
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